Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy

Romesh Khardori, MD, PhD; Anne L. Peters, MD


May 16, 2022

Disease burden in patients with type 2 diabetes is largely driven by the associated long-term complications, making glycemic control an invaluable treatment goal. In 2005, the first incretin-based agent was introduced into the type 2 diabetes treatment landscape to address postprandial glucose control. In the postprandial phase to control meal-related glycemic fluctuations, gut enteroendocrine cells release incretins, such as glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP). This results in glucose-dependent secretion of insulin and suppression of glucagon secretion; impaired insulin response to GLP-1 and GIP in patients with type 2 diabetes contributes to hyperglycemia. Thus, incretin-based therapy has become a popular choice for controlling blood glucose levels because of its glycemic efficacy, ease of use, and low risk for hypoglycemia.

How familiar are you with this therapeutic approach to type 2 diabetes? Test your knowledge with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.